JP2013537174A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537174A5
JP2013537174A5 JP2013527575A JP2013527575A JP2013537174A5 JP 2013537174 A5 JP2013537174 A5 JP 2013537174A5 JP 2013527575 A JP2013527575 A JP 2013527575A JP 2013527575 A JP2013527575 A JP 2013527575A JP 2013537174 A5 JP2013537174 A5 JP 2013537174A5
Authority
JP
Japan
Prior art keywords
amino
imidazo
cyclopropyl
methylbenzamide
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537174A (ja
JP5824050B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/065368 external-priority patent/WO2012032031A1/en
Publication of JP2013537174A publication Critical patent/JP2013537174A/ja
Publication of JP2013537174A5 publication Critical patent/JP2013537174A5/ja
Application granted granted Critical
Publication of JP5824050B2 publication Critical patent/JP5824050B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527575A 2010-09-10 2011-09-06 置換イミダゾピリダジン類 Expired - Fee Related JP5824050B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10176134 2010-09-10
EP10176134.4 2010-09-10
EP11075022.1 2011-02-04
EP11075022 2011-02-04
EP11170775 2011-06-21
EP11170771.7 2011-06-21
EP11170775.8 2011-06-21
EP11170771 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (en) 2010-09-10 2011-09-06 Substituted imidazopyridazines

Publications (3)

Publication Number Publication Date
JP2013537174A JP2013537174A (ja) 2013-09-30
JP2013537174A5 true JP2013537174A5 (enExample) 2014-10-09
JP5824050B2 JP5824050B2 (ja) 2015-11-25

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527575A Expired - Fee Related JP5824050B2 (ja) 2010-09-10 2011-09-06 置換イミダゾピリダジン類

Country Status (38)

Country Link
US (1) US9255100B2 (enExample)
EP (1) EP2614063B1 (enExample)
JP (1) JP5824050B2 (enExample)
KR (1) KR20140032337A (enExample)
CN (1) CN103370318B (enExample)
AP (1) AP3607A (enExample)
AR (1) AR082946A1 (enExample)
AU (1) AU2011298844B2 (enExample)
BR (1) BR112013005679A2 (enExample)
CA (1) CA2810755A1 (enExample)
CO (1) CO6720961A2 (enExample)
CR (1) CR20130102A (enExample)
CU (1) CU24187B1 (enExample)
CY (1) CY1117352T1 (enExample)
DK (1) DK2614063T3 (enExample)
DO (1) DOP2013000054A (enExample)
EA (1) EA023420B1 (enExample)
EC (1) ECSP13012752A (enExample)
ES (1) ES2568220T3 (enExample)
HR (1) HRP20160360T1 (enExample)
HU (1) HUE028771T2 (enExample)
IL (1) IL225058A (enExample)
MA (1) MA34516B1 (enExample)
ME (1) ME02389B (enExample)
MX (1) MX2013002713A (enExample)
MY (1) MY185139A (enExample)
NZ (1) NZ607904A (enExample)
PE (1) PE20131164A1 (enExample)
PH (1) PH12013500454A1 (enExample)
PL (1) PL2614063T3 (enExample)
RS (1) RS54661B1 (enExample)
SA (1) SA111320735B1 (enExample)
SG (1) SG188417A1 (enExample)
SI (1) SI2614063T1 (enExample)
TW (1) TWI541243B (enExample)
UY (1) UY33598A (enExample)
WO (1) WO2012032031A1 (enExample)
ZA (1) ZA201301756B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP2825540B1 (en) * 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US9586958B2 (en) 2013-06-11 2017-03-07 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
MX2015017245A (es) * 2013-06-13 2016-07-20 Bayer Pharma AG Combinacion de un derivado de imidazopiridazina y un agente mitotico para el tratamiento del cancer.
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物,其制备方法及用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CA2940237C (en) * 2014-02-21 2023-03-07 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201613927A (en) 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
DK3283642T3 (da) 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Prognostiske biomarkører til ttk-hæmmerbaseret kemoterapi
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
US10252918B2 (en) * 2015-12-04 2019-04-09 Exxonmobil Research And Engineering Company EMM-28, a novel synthetic crystalline material, its preparation and use
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN109476667B (zh) 2016-07-18 2022-06-28 大学健康网络 Ttk抑制剂的固体形式
US20200078142A1 (en) * 2017-04-11 2020-03-12 Straumann Holding Ag Dental implant
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
EP4447970A4 (en) * 2021-12-15 2025-10-22 Sillajen Inc PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCER
CN121002022A (zh) * 2023-01-19 2025-11-21 斯基霍克疗法公司 可用于调节剪接的组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
CN1308327C (zh) 2000-04-27 2007-04-04 安斯泰来制药有限公司 咪唑并吡啶衍生物
EP2292620A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
BRPI0618520A2 (pt) * 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
EP2474549A1 (en) * 2007-04-17 2012-07-11 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010124826A1 (en) * 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
WO2011113862A1 (en) 2010-03-18 2011-09-22 Bayer Pharma Aktiengesellschaft Imidazopyrazines
ES2555261T3 (es) 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
EP2651945A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2013545776A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
CA2821817A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
ES2530802T3 (es) 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
CN103370322B (zh) 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪

Similar Documents

Publication Publication Date Title
JP2013537174A5 (enExample)
JP6473457B2 (ja) Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
US10975080B2 (en) Compounds and compositions for inhibiting the activity of SHP2
CN109415360B (zh) 用于抑制shp2活性的化合物和组合物
US9926314B2 (en) Compounds and compositions for the treatment of parasitic diseases
US9555031B2 (en) Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
HRP20160360T1 (hr) Supstituirani imidazopiridazini
US20180289685A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
TWI682930B (zh) 治療性雜環化合物
JP2016505529A5 (enExample)
US20150291598A1 (en) Compounds and compositions for the treatment of parasitic diseases
JP2018517746A (ja) Shp2の活性を阻害するための化合物および組成物
JP2017502993A (ja) Shp2の活性を阻害するためのn−アザスピロシクロアルカン置換n−ヘテロアリール化合物および組成物
JP2016522232A5 (enExample)
TW200908969A (en) Organic compounds
EA019064B1 (ru) Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа
JP2019507122A (ja) クリプトスポリジウム症の治療のための化合物および組成物
JPWO2021021986A5 (enExample)
JPWO2020052631A5 (enExample)
RU2021107655A (ru) Соединения триазоло-пиримидина и их применение
HK40019993A (en) Therapeutic heterocyclic compounds